Trial Profile
Phase 1a/1b Trial of LTI-01 (Single Chain Urokinase, scuPA) Intrapleural Fibrinolytic Therapy (IPFT) in Patients with Complicated Parapneumonic Effusions or Empyema
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs LTI 01 (Primary)
- Indications Empyema; Pleural effusion
- Focus Adverse reactions
- Sponsors Lung Therapeutics
- 04 Jun 2019 Results presented at the Lung Therapeutics media release.
- 20 Jun 2018 Status changed from recruiting to discontinued.
- 14 Mar 2017 According to a Lung Therapeutics media release, first patient has been enrolled and dosed in the study.